PMID- 35313554
OWN - NLM
STAT- MEDLINE
DCOM- 20220404
LR  - 20220405
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 16
DP  - 2022
TI  - Changes of Optical Coherence Tomography Biomarkers in Macular Edema Secondary to 
      Retinal Vein Occlusion After Anti-VEGF and Anti-Inflammatory Therapies.
PG  - 717-725
LID - 10.2147/DDDT.S351683 [doi]
AB  - PURPOSE: This study aimed to assess the short-term changes of macular 
      microstructures following anti-VEGF and anti-inflammatory therapies in patients 
      with macular edema secondary to retinal vein occlusion (RVO-ME). PATIENTS AND 
      METHODS: In this retrospective study, 70 eyes of 70 patients with RVO-ME were 
      divided into the anti-VEGF (Group A, 35 eyes) and anti-inflammatory (Group B, 35 
      eyes) treatment groups. All patients underwent best-corrected visual acuity 
      (BCVA) assessment, intraocular pressure (IOP) assessment, slit lamp, fundus 
      fluorescein angiography (FA), scanning laser ophthalmoscopy (SLO), and 
      spectral-domain optical coherence tomography (SD-OCT). Group A received 
      intravitreal injection of 0.05 mL anti-VEGF antibodies (Lucentis((R)) or 
      Aflibercept((R))) monthly for 3 consecutive months, while Group B received 0.7 mg 
      dexamethasone (Ozurdex((R))) single intravitreal injection. BCVA and SD-OCT 
      biomarkers were recorded at baseline and 3 months after the first injection. 
      Changes of BCVA and SD-OCT biomarkers following these treatments were compared 
      between the two groups. RESULTS: BCVA and SD-OCT biomarkers, except choroidal 
      thickness, in both groups were significantly improved after treatment (all P < 
      0.01). At 3 months, the height of serous retinal detachment (SRD) was markedly 
      lower (P = 0.006), with significantly less hyperreflective dots (HRD, P = 0.037) 
      in Group B compared with Group A. Other SD-OCT biomarkers and BCVA were not 
      significantly different between the two groups (all P > 0.05). CONCLUSION: 
      Anti-VEGF and anti-inflammatory therapies are both effective in RVO-ME, with 
      improvement in BCVA and SD-OCT biomarkers. Anti-inflammatory therapy may be more 
      effective than anti-VEGF therapy in SRD and HRD resolution.
CI  - (c) 2022 Ding et al.
FAU - Ding, Xuefei
AU  - Ding X
AD  - Department of Ophtalmology, Henan Eye Hospital, The First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, People's Republic of China.
FAU - Hu, Yijun
AU  - Hu Y
AD  - Department of Ophthalmology, Guangdong Eye Institute, Guangdong Provincial 
      People' s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, People's 
      Republic of China.
AD  - Refractive Surgery Center, Aier Institute of Refractive Surgery, Guangzhou Aier 
      Eye Hospital, Guangzhou, People's Republic of China.
FAU - Yu, Honghua
AU  - Yu H
AD  - Department of Ophthalmology, Guangdong Eye Institute, Guangdong Provincial 
      People' s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, People's 
      Republic of China.
FAU - Li, Qiuming
AU  - Li Q
AD  - Department of Ophtalmology, Henan Eye Hospital, The First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20220315
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Anti-Inflammatory Agents/pharmacology/therapeutic use
MH  - Biomarkers
MH  - Humans
MH  - *Macular Edema/diagnostic imaging/drug therapy
MH  - *Retinal Vein Occlusion/complications/drug therapy
MH  - Retrospective Studies
MH  - Tomography, Optical Coherence/methods
MH  - Visual Acuity
PMC - PMC8934115
OTO - NOTNLM
OT  - SD-OCT
OT  - anti-VEGF therapy
OT  - anti-inflammatory therapy
OT  - biomarkers
OT  - macular edema
COIS- The authors declare that there are no conflicts of interest in this work.
EDAT- 2022/03/23 06:00
MHDA- 2022/04/05 06:00
PMCR- 2022/03/15
CRDT- 2022/03/22 05:07
PHST- 2021/11/29 00:00 [received]
PHST- 2022/02/18 00:00 [accepted]
PHST- 2022/03/22 05:07 [entrez]
PHST- 2022/03/23 06:00 [pubmed]
PHST- 2022/04/05 06:00 [medline]
PHST- 2022/03/15 00:00 [pmc-release]
AID - 351683 [pii]
AID - 10.2147/DDDT.S351683 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2022 Mar 15;16:717-725. doi: 10.2147/DDDT.S351683. 
      eCollection 2022.